<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03032016</url>
  </required_header>
  <id_info>
    <org_study_id>DF VOD-2013-03-REG</org_study_id>
    <nct_id>NCT03032016</nct_id>
  </id_info>
  <brief_title>European VOD Registry</brief_title>
  <official_title>A Multi-centre, Multinational, Prospective Observational Registry to Collect Safety and Outcome Data in Patients Diagnosed With Severe Hepatic VOD Following Hematopoietic Stem Cell Transplantation (HSCT) and Treated With Defitelio® or Supportive Care (Control Group)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jazz Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Group for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following the licencing of a new drug, Defitelio®, indicated for the treatment of severe
      Veno-Occlusive Disease of the liver (sVOD), a rare but serious complication of haematopoietic
      stem cell transplantation (HSCT), the pharmaceutical company that manufactures Defitelio®
      (Gentium, a Jazz Pharmaceuticals Company) - as a specific obligation (SOB) - has been
      required by PRAC (Pharmacovigilance Risk Assessment Committee) to set up a disease registry
      to collect safety and outcome data, and to assess patterns of utilization of Defitelio® in
      the post-approval setting. This registry is a Post Authorization Safety Study (PASS), which
      is being coordinated through the European Society for Blood and Marrow Transplantation
      (EBMT). Following appropriate consent, data from patients who undergo haematopoietic stem
      cell transplantation are routinely collected at the local centre for the EBMT database. For
      this study, the sites are being asked to collect additional anonymised clinical data from
      patients who develop this complication or who have been treated with Defitelio® for other
      reasons than sVOD. The study simply requires collection of data which is already recorded in
      the patient charts, but not routinely collected.

      The study DOES NOT involve decisions about treatment, which are clinical decisions, but
      merely collection of data for patients who develop this complication, whether or not they
      receive treatment and for patients who are treated with Defitelio® for any other reasons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Defitelio® has been granted a Marketing Authorisation in Europe under exceptional
      circumstances. Defitelio® is indicated for the treatment of severe hepatic Veno-Occlusive
      Disease (sVOD) also known as sinusoidal obstruction syndrome (SOS) in haematopoietic
      stem-cell transplantation (HSCT) therapy.

      It is indicated in adults and in adolescents, children and infants over 1 month of age.

      As a specific obligation (SOB), Gentium has been required to set up a disease registry to
      collect safety and outcome data, and to assess patterns of utilization of Defitelio® in the
      post-approval setting.

      This is a multi-centre, multinational and prospective observational disease registry of
      patients with severe hepatic VOD following HSCT, to record patients treated with Defitelio®
      or supportive care.

      Gentium has been required to ensure that information regarding all potential and identified
      risks reported in the most recent version of the Risk Management Plan is being collected.

      Hepatic VOD is one of the most common life-threatening regimen-related toxicities that
      constitutes a barrier to successful allogeneic and autologous HSCT. VOD is characterised by
      rapid weight gain, painful hepatomegaly, hyperbilirubinemia/jaundice, and ascites/fluid
      retention, without other identifiable causes for liver disease (Richardson, 2012). In a
      recent survey on 135 studies performed between 1997 and October 2007, the overall mean
      incidence of VOD has been reported to be 13.7% with a lower rate of 9.6% when Baltimore
      criteria were applied (Coppell, 2010).

      The severe form of the disease, usually associated with pulmonary dysfunction and/or renal
      dysfunction (ie, multi-organ failure, MOF), with or without encephalopathy, and a mortality
      rate of more than 80% by 100 days after HSCT, is reported to occur in about 40%-60% of VOD
      patients, that is approximately 3-5% of transplanted patients.

      Given the low incidence of sVOD and the varying size of bone marrow transplant centres in EU,
      in order to collect meaningful clinical data, the registry will be conducted in European
      transplant centres only in which the overall number of transplant is at least 100 per year.

      The main objective of the registry is to assess the incidence rate of specific SAEs (Serious
      Adverse Events) of interest (including fatalities) in patients with severe hepatic VOD
      treated with Defitelio® and to compare these rates with those occurring in a similar
      population not treated with Defitelio®.

      Secondary objectives are:

        -  To describe the population treated with Defibrotide and controls (age, gender,
           ethnicity, patients with pre-existing liver or severe renal insufficiency; patient with
           intrinsic lung disease)

        -  To determine the incidence rate of multiorgan failure (MOF) and Graft versus host
           disease (GvHD) in adult and paediatric patients receiving Defibrotide and in controls

        -  To determine survival by Day+100 post-HSCT, overall mortality and mortality due to VOD
           in patients treated with Defibrotide and in controls

        -  To determine the rate of VOD/MOF resolution any time after treatment initiation in
           patients treated with Defibrotide and in controls.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence rate of specific SAE of interest</measure>
    <time_frame>over 12 months</time_frame>
    <description>Assess the incidence rate of specific SAEs of interest (including fatalities) in patients with severe hepatic VOD treated with Defitelio® and to compare these rates with those occurring in a similar population not treated with Defitelio®.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Describe the population</measure>
    <time_frame>Enrolment</time_frame>
    <description>To describe the population treated with Defitelio® and controls (age, gender, ethnicity, patients with pre-existing liver or severe renal insufficiency; patient with intrinsic lung disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GvHD incidence</measure>
    <time_frame>over 12 months</time_frame>
    <description>Determine the incidence rate of Graft versus host disease (GvHD) in adult and paediatric patients receiving Defitelio® and in controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>over 12 months</time_frame>
    <description>To determine survival by Day+100 post-HSCT, overall mortality and mortality due to VOD in patients treated with Defitelio® and in controls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VOD/MOF Resolution</measure>
    <time_frame>over 12 months</time_frame>
    <description>To determine the rate of Veno Occlusive Disease/Multi Organ Failure resolution any time after treatment initiation in patients treated with Defitelio® and in controls.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Hepatic Veno-Occlusive Disease</condition>
  <arm_group>
    <arm_group_label>sVOD patient treated with defibrotide</arm_group_label>
    <description>Patient diagnosed with severe hepatic VOD and treated with defibrotide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sVOD patient under supportive care</arm_group_label>
    <description>Patient diagnosed with severe hepatic VOD and treated with supportive care only</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        The patients will be selected by the treating physicians working in hospitals being part of
        the European society for Bone Marrow Transplantation network.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing hematopoietic stem cell transplantation and diagnosed with severe
             hepatic VOD, who agree to participate in the study (Main population).

          -  Patients treated with defibrotide for another condition than severe hepatic VOD
             (Secondary population) in the scope of hematopoietic stem cell transplantation .

        Exclusion Criteria:

          -  There will not be any specific exclusion criteria; however contraindications, special
             warnings and precautions for use as detailed in the SPC will have to be considered by
             the treating physician.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamad Mohty</last_name>
    <role>Study Director</role>
    <affiliation>European Society for Blood and Marrow Transplantation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuelle Polge</last_name>
    <phone>+33.1.71.97.04.85</phone>
    <email>emmanuelle.polge@upmc.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jessica Lemaitre</last_name>
    <phone>+33.1.70.64.24.15</phone>
    <email>jessica.lemaitre@upmc.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU Angers, Maladies du Sang</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvie Francois, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Sylvie Francois, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Bordeaux Groupe hospitalier Pellegrin Enfants</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Jubert, MD</last_name>
    </contact>
    <investigator>
      <last_name>Charlotte Jubert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU d'Estaing</name>
      <address>
        <city>Clermont Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Olivier Bay, Prof</last_name>
    </contact>
    <investigator>
      <last_name>J-O Bay</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yakoub-Agha Ibrahim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bénédicte Bruno, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bénédicte Bruno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Girault, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Stephane Girault</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHOP</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Renard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Cécile Renard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital d'enfants de la Timone</name>
      <address>
        <city>Mare aux Daims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gérard Michel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gérard Michel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Blaise, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Didier Blaise</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Fegueux, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nathalie Fegueux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice Chevallier, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Patrice Chevallier, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de l'ARCHET</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Cluzeau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Cluzeau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mor Seny Gueye</last_name>
    </contact>
    <investigator>
      <last_name>Mohamad Mohty, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Robert Debré</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>jean-hugues Dalle, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Hugues Dalle, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Lotz, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Lotz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Michon, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean Michon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edouard Forcade, MD</last_name>
    </contact>
    <investigator>
      <last_name>Edouard Forcade, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Miletrie</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natacha Maillard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Natacha Maillard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Lioure, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bruno Lioure, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IUTC Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Huynh, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne Huynh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy (Pediatrics)</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle Dufour, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christelle Dufour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J H Bourhis, MD</last_name>
    </contact>
    <investigator>
      <last_name>J H Bourhis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Rambaldi, Prof, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Rambaldi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Oncoematologia Ospedale Pediatrico Mayer</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Tintori, MD</last_name>
    </contact>
    <investigator>
      <last_name>Veronica Tintori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Careggi</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Bosi, Prof</last_name>
    </contact>
    <investigator>
      <last_name>alberto Bosi, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institute G. Gaslini</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maura Faraci, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maura Faraci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Ca' Granda Ospedale Maggiore di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Onida, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francesco Onida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale di Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Grillo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Giovanni Grillo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Trinca</last_name>
    </contact>
    <investigator>
      <last_name>Fabio Ciceri, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica di oncoematologia pediatrica</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabetta Calore, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabetta Calore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Zecca, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marco Zecca, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria de la Misericorda</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katia Perruccio, MD</last_name>
    </contact>
    <investigator>
      <last_name>Katia Perruccio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Cimminiello, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michele Cimminiello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRRCS Ospedale Pediatrico Bambino Gesù</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franco Locatelli, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Franco Locatelli, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica S. Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>La Sapienza University Hospital</name>
      <address>
        <city>Rome</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Foa, Prof, MD</last_name>
    </contact>
    <investigator>
      <last_name>Roberto Foa, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Citta della salute e delle Scienza</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benedetto Bruno, MD</last_name>
    </contact>
    <investigator>
      <last_name>Benedetto Bruno, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Infantile Regina Margherita</name>
      <address>
        <city>Torino</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franca Fagioli, MD</last_name>
    </contact>
    <investigator>
      <last_name>Franca Fagioli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto per l'Infanzia IRCCS Burlo Garofolo</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia Maximova, MD</last_name>
    </contact>
    <investigator>
      <last_name>Natalia Maximova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Ematologica-Azienda Ospedaliero Universitaria</name>
      <address>
        <city>Udine</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Lisa Battista, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marta Lisa Battista, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Rossi, Clinica di Oncoematologia Pediatrica</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simone Cesaro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Simone Cesaro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inst. Portugues Oncologia o Lisboa</name>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuno Miranda, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nuno Miranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Children's Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Lawson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sarah Lawson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Birmingham Heartlands Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manos Nikolousis</last_name>
    </contact>
    <investigator>
      <last_name>Manos Nokolousis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Hospital for Children</name>
      <address>
        <city>Bristol</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Gassas, MD</last_name>
    </contact>
    <investigator>
      <last_name>Adam Gassas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Ormond Street Hospital Children's Charity</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Chieasa</last_name>
    </contact>
    <investigator>
      <last_name>Robert Chiesa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Imperial College</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Olavarria</last_name>
    </contact>
    <investigator>
      <last_name>Edouardo Olavarria, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St George's Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mickey Koh, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Mickey Koh, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Wynn, MD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Wynn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great North Children's Hospital</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Gennery</last_name>
    </contact>
    <investigator>
      <last_name>Andrew Gennery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Lawson</last_name>
    </contact>
    <investigator>
      <last_name>Sarah Lawson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radccliffe Children's Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Wheeler, MD</last_name>
    </contact>
    <investigator>
      <last_name>Kate Wheeler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Plymouth Hospitals NHS Trust</name>
      <address>
        <city>Plymouth</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Hunter, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hannah Hunter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Ireland</country>
  </removed_countries>
  <link>
    <url>http://www.ebmt.org/ebmt-studies/vod-project</url>
    <description>Home page of the European VOD Registry on EBMT Website</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2017</study_first_submitted>
  <study_first_submitted_qc>January 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2017</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VOD</keyword>
  <keyword>Defibrotide</keyword>
  <keyword>Defitelio</keyword>
  <keyword>Registry</keyword>
  <keyword>SOS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Veno-Occlusive Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Defibrotide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

